Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Mansur, RB; Ahmed, J; Cha, DS; Woldeyohannes, HO; Subramaniapillai, M; Lovshin, J; Lee, JG; Lee, JH; Brietzke, E; Reininghaus, EZ; Sim, K; Vinberg, M; Rasgon, N; Hajek, T; McIntyre, RS.
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study.
J Affect Disord. 2017; 207(1):114-120
Doi: 10.1016/j.jad.2016.09.056
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Reininghaus Eva
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- There is a paucity of treatments that are capable of reliably and robustly improving cognitive function in adults with mood disorders. Glucagon-like peptide-1 is synthesized centrally and its receptors are abundantly expressed in neural circuits subserving cognitive function. We aimed to determine the effects of liraglutide, a GLP-1 receptor (GLP-1R) agonist, on objective measures of cognition in adults with a depressive or bipolar disorder. In this 4-week, pilot, open-label, domain-based study (e.g. cognition), we recruited 19 individuals with major depressive disorder (MDD) or bipolar disorder (BD) and an impairment in executive function, defined as a below-average performance in the Trail Making Test-B (TMTB). Liraglutide 1.8mg/day was added as an adjunct to existing pharmacotherapy. Participants had significant increases from baseline to week 4 in the TMTB standard score (age and education corrected) (Cohen's d=0.64, p=0.009) and in a composite Z-score comprising multiple cognitive tests (i.e. Digit Symbol Substitution Test, Rey Auditory Verbal Learning Test, Stroop test) (Cohen's d=0.77, p<0.001). Neither changes in mood rating scales nor metabolic parameters were associated with changes in cognitive performance (all p>0.05); however baseline insulin resistance (IR) and body mass index (BMI) moderated the changes in the composite Z-score (p=0.021 and p=0.046, respectively), indicating larger responses in individuals with higher IR and BMI at baseline. There was a significant increase in lipase (p<0.001), but individual values were above the upper limit of normality. Small sample size, open-label design, lack of a placebo group. Liraglutide was safe and well tolerated by a sample of non-diabetic individuals with mood disorders and had beneficial effects on objective measures of cognitive function. Larger studies with controlled trial designs are necessary to confirm and expand the results described herein. Copyright © 2016 Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Affect -
- Bipolar Disorder - drug therapy
- Bipolar Disorder - psychology
- Cognition -
- Cognitive Dysfunction - drug therapy
- Cognitive Dysfunction - psychology
- Depressive Disorder, Major - drug therapy
- Depressive Disorder, Major - psychology
- Executive Function -
- Female -
- Humans -
- Incretins - therapeutic use
- Liraglutide - therapeutic use
- Male -
- Middle Aged -
- Mood Disorders - drug therapy
- Mood Disorders - psychology
- Nausea - chemically induced
- Pilot Projects -
- Stroop Test -
- Treatment Outcome -
- Verbal Learning -
- Find related publications in this database (Keywords)
- Major depressive disorder
- Bipolar disorder
- Cognition
- Glucagon-like peptide-1
- Liraglutide
- Insulin resistance